Exactmer owns the Nanostar Sieving technology platform. This employs iterative, liquid-phase chemistry coupled to membrane purification, to create polymers of outstanding purity. Exactmer is currently advancing the production of oligonucleotides at scale, bringing these advanced therapeutics to all patients in need. Nanostar Sieving can also produce unimolecular polyethylene glycols (PEGs), including a disruptive new suite of 'multi-functionalised PEGs', with handles for conjugation along the polymer backbone; ideal linkers molecules for Antibody Drug Conjugates.